{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T01:54:12Z","timestamp":1793757252795,"version":"4.6.1"},"reference-count":68,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,10,29]],"date-time":"2018-10-29T00:00:00Z","timestamp":1540771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2018,10,29]],"date-time":"2018-10-29T00:00:00Z","timestamp":1540771200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004359","name":"Vetenskapsr&amp;#x00E5;det","doi-asserted-by":"publisher","award":["2016-01381"],"award-info":[{"award-number":["2016-01381"]}],"id":[{"id":"10.13039\/501100004359","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"U.S. Department of Health &amp; Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["CA71508"],"award-info":[{"award-number":["CA71508"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Secreted FGF binding proteins (FGFBP) mobilize locally-acting paracrine FGFs from their extracellular storage. Here, we report that FGFBP3 (BP3) modulates fat and glucose metabolism in mouse models of metabolic syndrome. BP3 knockout mice exhibited altered lipid metabolism pathways with reduced hepatic and serum triglycerides. In obese mice the expression of exogenous BP3 reduced hyperglycemia, hepatosteatosis and weight gain, blunted de novo lipogenesis in liver and adipose tissues, increased circulating adiponectin and decreased NEFA. The BP3 protein interacts with endocrine FGFs through its C-terminus and thus enhances their signaling. We propose that BP3 may constitute a new therapeutic to reverse the pathology associated with metabolic syndrome that includes nonalcoholic fatty liver disease and type 2 diabetes mellitus.<\/jats:p>","DOI":"10.1038\/s41598-018-34238-5","type":"journal-article","created":{"date-parts":[[2018,10,23]],"date-time":"2018-10-23T14:00:35Z","timestamp":1540303235000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":26,"title":["Fibroblast Growth Factor Binding Protein 3 (FGFBP3) impacts carbohydrate and lipid metabolism"],"prefix":"10.1038","volume":"8","author":[{"given":"Elena","family":"Tassi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khalid A.","family":"Garman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcel O.","family":"Schmidt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoting","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khaled W.","family":"Kabbara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aykut","family":"Uren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"York","family":"Tomita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Regina","family":"Goetz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moosa","family":"Mohammadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher S.","family":"Wilcox","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna T.","family":"Riegel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mattias","family":"Carlstrom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0570-4950","authenticated-orcid":false,"given":"Anton","family":"Wellstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,10,29]]},"reference":[{"key":"34238_CR1","doi-asserted-by":"publisher","first-page":"10263","DOI":"10.1074\/jbc.M011493200","volume":"276","author":"M Mongiat","year":"2001","unstructured":"Mongiat, M. et al. Fibroblast growth factor-binding protein is a novel partner for perlecan protein core. J Biol Chem 276, 10263\u201310271 (2001).","journal-title":"J Biol Chem"},{"key":"34238_CR2","doi-asserted-by":"publisher","first-page":"40247","DOI":"10.1074\/jbc.M104933200","volume":"276","author":"E Tassi","year":"2001","unstructured":"Tassi, E. et al. Enhancement of fibroblast growth factor (FGF) activity by an FGF-binding protein. J Biol Chem 276, 40247\u201340253 (2001).","journal-title":"J Biol Chem"},{"key":"34238_CR3","doi-asserted-by":"publisher","first-page":"5269","DOI":"10.1038\/sj.onc.1208560","volume":"24","author":"H-D Beer","year":"2005","unstructured":"Beer, H.-D. et al. The fibroblast growth factor binding protein is a novel interaction partner of FGF-7, FGF-10 and FGF-22 and regulates FGF activity: implications for epithelial repair. Oncogene 24, 5269\u20135277 (2005).","journal-title":"Oncogene"},{"key":"34238_CR4","doi-asserted-by":"publisher","first-page":"28329","DOI":"10.1074\/jbc.M802144200","volume":"283","author":"W Zhang","year":"2008","unstructured":"Zhang, W. et al. Effect of FGF-binding protein 3 on vascular permeability. J Biol Chem 283, 28329\u201328337 (2008).","journal-title":"J Biol Chem"},{"key":"34238_CR5","doi-asserted-by":"publisher","first-page":"R105","DOI":"10.1152\/ajpregu.00492.2005","volume":"290","author":"PE Ray","year":"2006","unstructured":"Ray, P. E., Tassi, E., Liu, X.-H. & Wellstein, A. Role of fibroblast growth factor-binding protein in the pathogenesis of HIV-associated hemolytic uremic syndrome. Am J Physiol Regul Integr Comp Physiol 290, R105\u201313 (2006).","journal-title":"Am J Physiol Regul Integr Comp Physiol"},{"key":"34238_CR6","doi-asserted-by":"publisher","first-page":"8585","DOI":"10.1073\/pnas.0810952106","volume":"106","author":"KA Gibby","year":"2009","unstructured":"Gibby, K. A., McDonnell, K., Schmidt, M. O. & Wellstein, A. A distinct role for secreted fibroblast growth factor-binding proteins in development. Proc Natl Acad Sci USA 106, 8585\u20138590 (2009).","journal-title":"Proc Natl Acad Sci USA"},{"key":"34238_CR7","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1038\/labinvest.3700269","volume":"85","author":"K McDonnell","year":"2005","unstructured":"McDonnell, K. et al. Vascular leakage in chick embryos after expression of a secreted binding protein for fibroblast growth factors. Lab Invest 85, 747\u2013755 (2005).","journal-title":"Lab Invest"},{"key":"34238_CR8","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1038\/nm1097-1137","volume":"3","author":"F Czubayko","year":"1997","unstructured":"Czubayko, F. et al. A secreted FGF-binding protein can serve as the angiogenic switch in human cancer. Nat Med 3, 1137\u20131140 (1997).","journal-title":"Nat Med"},{"key":"34238_CR9","first-page":"8085","volume":"63","author":"R Ray","year":"2003","unstructured":"Ray, R. et al. Up-regulation of fibroblast growth factor-binding protein, by beta-catenin during colon carcinogenesis. Cancer Research 63, 8085\u20138089 (2003).","journal-title":"Cancer Research"},{"key":"34238_CR10","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1158\/0008-5472.CAN-05-2926","volume":"66","author":"E Tassi","year":"2006","unstructured":"Tassi, E. et al. Expression of a fibroblast growth factor-binding protein during the development of adenocarcinoma of the pancreas and colon. Cancer Research 66, 1191\u20131198 (2006).","journal-title":"Cancer Research"},{"key":"34238_CR11","doi-asserted-by":"crossref","first-page":"28243","DOI":"10.1016\/S0021-9258(18)46920-7","volume":"269","author":"F Czubayko","year":"1994","unstructured":"Czubayko, F., Smith, R. V., Chung, H. C. & Wellstein, A. Tumor growth and angiogenesis induced by a secreted binding protein for fibroblast growth factors. J Biol Chem 269, 28243\u201328248 (1994).","journal-title":"J Biol Chem"},{"key":"34238_CR12","doi-asserted-by":"publisher","DOI":"10.1186\/1476-4598-10-144","volume":"10","author":"D Schulze","year":"2011","unstructured":"Schulze, D., Plohmann, P., Hobel, S. & Aigner, A. Anti-tumor effects of fibroblast growth factor-binding protein (FGF-BP) knockdown in colon carcinoma. Mol Cancer 10, 144 (2011).","journal-title":"Mol Cancer"},{"key":"34238_CR13","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1593\/neo.04214","volume":"6","author":"A Kurtz","year":"2004","unstructured":"Kurtz, A. et al. Differential regulation of a fibroblast growth factor-binding protein during skin carcinogenesis and wound healing. Neoplasia 6, 595\u2013602 (2004).","journal-title":"Neoplasia"},{"key":"34238_CR14","doi-asserted-by":"publisher","first-page":"1360","DOI":"10.1161\/hc1102.106792","volume":"105","author":"C Napoli","year":"2002","unstructured":"Napoli, C. et al. Maternal hypercholesterolemia during pregnancy promotes early atherogenesis in LDL receptor-deficient mice and alters aortic gene expression determined by microarray. Circulation 105, 1360\u20131367 (2002).","journal-title":"Circulation"},{"key":"34238_CR15","doi-asserted-by":"publisher","first-page":"R775","DOI":"10.1152\/ajpregu.00737.2006","volume":"293","author":"E Tassi","year":"2007","unstructured":"Tassi, E. et al. Effects on neurite outgrowth and cell survival of a secreted fibroblast growth factor binding protein upregulated during spinal cord injury. Am J Physiol Regul Integr Comp Physiol 293, R775\u201383 (2007).","journal-title":"Am J Physiol Regul Integr Comp Physiol"},{"key":"34238_CR16","doi-asserted-by":"publisher","first-page":"1549","DOI":"10.1126\/science.1181046","volume":"326","author":"AH Williams","year":"2009","unstructured":"Williams, A. H. et al. MicroRNA-206 delays ALS progression and promotes regeneration of neuromuscular synapses in mice. Science (New York, NY) 326, 1549\u20131554 (2009).","journal-title":"Science (New York, NY)"},{"key":"34238_CR17","doi-asserted-by":"publisher","first-page":"2220","DOI":"10.1016\/j.ajpath.2011.07.043","volume":"179","author":"E Tassi","year":"2011","unstructured":"Tassi, E. et al. Impact of fibroblast growth factor-binding protein-1 expression on angiogenesis and wound healing. Am J Pathol 179, 2220\u20132232 (2011).","journal-title":"Am J Pathol"},{"issue":"1","key":"34238_CR18","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1161\/HYPERTENSIONAHA.117.10268","volume":"71","author":"Elena Tassi","year":"2018","unstructured":"Tassi, E. et al. Blood Pressure Control by a Secreted FGFBP1 (Fibroblast Growth Factor-Binding Protein). Hypertension 71, 160\u2013167 (2018).","journal-title":"Hypertension"},{"key":"34238_CR19","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/j.jid.2017.07.847","volume":"138","author":"MO Schmidt","year":"2018","unstructured":"Schmidt, M. O. et al. The Role of Fibroblast GrowthFactor-Binding Protein 1 in SkinCarcinogenesis and Inflammation. J Invest Dermatol 138, 179\u2013188 (2018).","journal-title":"J Invest Dermatol"},{"key":"34238_CR20","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1101\/gad.184788.111","volume":"26","author":"MJ Potthoff","year":"2012","unstructured":"Potthoff, M. J., Kliewer, S. A. & Mangelsdorf, D. J. Endocrine fibroblast growth factors 15\/19 and 21: from feast to famine. Genes Dev 26, 312\u2013324 (2012).","journal-title":"Genes Dev"},{"key":"34238_CR21","doi-asserted-by":"publisher","first-page":"2404","DOI":"10.1002\/hep.25929","volume":"56","author":"C Cicione","year":"2012","unstructured":"Cicione, C., Degirolamo, C. & Moschetta, A. Emerging role of fibroblast growth factors 15\/19 and 21 as metabolic integrators in the liver. Hepatology 56, 2404\u20132411 (2012).","journal-title":"Hepatology"},{"key":"34238_CR22","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1016\/j.cmet.2012.11.001","volume":"16","author":"B Angelin","year":"2012","unstructured":"Angelin, B., Larsson, T. E. & Rudling, M. Circulating fibroblast growth factors as metabolic regulators\u2013a critical appraisal. Cell Metab 16, 693\u2013705 (2012).","journal-title":"Cell Metab"},{"key":"34238_CR23","first-page":"943162","volume":"2014","author":"J Kaur","year":"2014","unstructured":"Kaur, J. A comprehensive review on metabolic syndrome. Cardiol Res Pract 2014, 943162 (2014).","journal-title":"Cardiol Res Pract"},{"key":"34238_CR24","doi-asserted-by":"publisher","first-page":"2063","DOI":"10.1056\/NEJMra1503519","volume":"377","author":"AM Diehl","year":"2017","unstructured":"Diehl, A. M. & Day, C. Cause, Pathogenesis, and Treatment of Nonalcoholic Steatohepatitis. N Engl J Med 377, 2063\u20132072 (2017).","journal-title":"N Engl J Med"},{"key":"34238_CR25","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1016\/j.bbalip.2014.09.023","volume":"1851","author":"M Masoodi","year":"2015","unstructured":"Masoodi, M., Kuda, O., Rossmeisl, M., Flachs, P. & Kopecky, J. Lipid signaling in adipose tissue: Connecting inflammation & metabolism. Biochim Biophys Acta 1851, 503\u2013518 (2015).","journal-title":"Biochim Biophys Acta"},{"key":"34238_CR26","doi-asserted-by":"publisher","first-page":"2199","DOI":"10.2337\/db07-1087","volume":"57","author":"AG G\u00f3mez-Valad\u00e9s","year":"2008","unstructured":"G\u00f3mez-Valad\u00e9s, A. G. et al. Pck1 gene silencing in the liver improves glycemia control, insulin sensitivity, and dyslipidemia in db\/db mice. Diabetes 57, 2199\u20132210 (2008).","journal-title":"Diabetes"},{"key":"34238_CR27","doi-asserted-by":"publisher","first-page":"3391","DOI":"10.2337\/diabetes.51.12.3391","volume":"51","author":"JJ Senn","year":"2002","unstructured":"Senn, J. J., Klover, P. J., Nowak, I. A. & Mooney, R. A. Interleukin-6 induces cellular insulin resistance in hepatocytes. Diabetes 51, 3391\u20133399 (2002).","journal-title":"Diabetes"},{"key":"34238_CR28","doi-asserted-by":"publisher","first-page":"1946","DOI":"10.1096\/fj.08-125674","volume":"23","author":"A Gonz\u00e1lez-P\u00e9riz","year":"2009","unstructured":"Gonz\u00e1lez-P\u00e9riz, A. et al. Obesity-induced insulin resistance and hepatic steatosis are alleviated by omega-3 fatty acids: a role for resolvins and protectins. FASEB J 23, 1946\u20131957 (2009).","journal-title":"FASEB J"},{"key":"34238_CR29","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1172\/JCI27794","volume":"116","author":"BN Finck","year":"2006","unstructured":"Finck, B. N. & Kelly, D. P. PGC-1 coactivators: inducible regulators of energy metabolism in health and disease. J Clin Invest 116, 615\u2013622 (2006).","journal-title":"J Clin Invest"},{"key":"34238_CR30","doi-asserted-by":"publisher","first-page":"2283","DOI":"10.1194\/jlr.R800018-JLR200","volume":"49","author":"C-LE Yen","year":"2008","unstructured":"Yen, C.-L. E., Stone, S. J., Koliwad, S., Harris, C. & Farese, R. V. Jr. Thematic Review Series: Glycerolipids.DGAT enzymes and triacylglycerol biosynthesis. J Lipid Res 49, 2283\u20132301 (2008).","journal-title":"J Lipid Res"},{"key":"34238_CR31","doi-asserted-by":"publisher","first-page":"296537","DOI":"10.1155\/2013\/296537","volume":"2013","author":"JW Perfield","year":"2013","unstructured":"Perfield, J. W. et al. Altered hepatic lipid metabolism contributes to nonalcoholic fatty liver disease in leptin-deficient Ob\/Ob mice. J Obes 2013, 296537 (2013).","journal-title":"J Obes"},{"key":"34238_CR32","first-page":"177","volume":"59","author":"G Wolf","year":"2001","unstructured":"Wolf, G. Insulin resistance associated with leptin deficiency in mice: a possible model for noninsulin-dependent diabetes mellitus. Nutr Rev 59, 177\u2013179 (2001).","journal-title":"Nutr Rev"},{"key":"34238_CR33","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1242\/dmm.003467","volume":"3","author":"AJ Kennedy","year":"2010","unstructured":"Kennedy, A. J., Ellacott, K. L. J., King, V. L. & Hasty, A. H. Mouse models of the metabolic syndrome. Dis Model Mech 3, 156\u2013166 (2010).","journal-title":"Dis Model Mech"},{"key":"34238_CR34","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1172\/JCI34275","volume":"118","author":"C Postic","year":"2008","unstructured":"Postic, C. & Girard, J. Contribution of de novo fatty acid synthesis to hepatic steatosis and insulin resistance: lessons from genetically engineered mice. J Clin Invest 118, 829\u2013838 (2008).","journal-title":"J Clin Invest"},{"key":"34238_CR35","doi-asserted-by":"crossref","unstructured":"Shimomura, I., Bashmakov, Y. & Horton, J. D. Increased levels of nuclear SREBP-1c associated with fatty livers in two mouse models of diabetes mellitus. 274, 30028\u201330032 (1999).","DOI":"10.1074\/jbc.274.42.30028"},{"key":"34238_CR36","first-page":"194","volume":"4","author":"Y Luo","year":"2013","unstructured":"Luo, Y. & McKeehan, W. L. Stressed Liver and Muscle Call on Adipocytes with FGF21. Front Endocrinol (Lausanne) 4, 194 (2013).","journal-title":"Front Endocrinol (Lausanne)"},{"key":"34238_CR37","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1172\/JCI0215593","volume":"109","author":"JD Horton","year":"2002","unstructured":"Horton, J. D., Goldstein, J. L. & Brown, M. S. SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver. J Clin Invest 109, 1125\u20131131 (2002).","journal-title":"J Clin Invest"},{"key":"34238_CR38","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1038\/nm980","volume":"10","author":"H Inoue","year":"2004","unstructured":"Inoue, H. et al. Role of STAT-3 in regulation of hepatic gluconeogenic genes and carbohydrate metabolism in vivo. Nat Med 10, 168\u2013174 (2004).","journal-title":"Nat Med"},{"key":"34238_CR39","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1038\/nrm1837","volume":"7","author":"CM Taniguchi","year":"2006","unstructured":"Taniguchi, C. M., Emanuelli, B. & Kahn, C. R. Critical nodes in signalling pathways: insights into insulin action. Nat Rev Mol Cell Biol 7, 85\u201396 (2006).","journal-title":"Nat Rev Mol Cell Biol"},{"key":"34238_CR40","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1038\/aps.2011.203","volume":"33","author":"C Nilsson","year":"2012","unstructured":"Nilsson, C., Raun, K., Yan, F.-F., Larsen, M. O. & Tang-Christensen, M. Laboratory animals as surrogate models of human obesity. Acta Pharmacol Sin 33, 173\u2013181 (2012).","journal-title":"Acta Pharmacol Sin"},{"key":"34238_CR41","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1038\/nrm3528","volume":"14","author":"R Goetz","year":"2013","unstructured":"Goetz, R. & Mohammadi, M. Exploring mechanisms of FGF signalling through the lens of structural biology. Nat Rev Mol Cell Biol 14, 166\u2013180 (2013).","journal-title":"Nat Rev Mol Cell Biol"},{"key":"34238_CR42","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1074\/jbc.M510754200","volume":"281","author":"B Xie","year":"2006","unstructured":"Xie, B. et al. Identification of the fibroblast growth factor (FGF)-interacting domain in a secreted FGF-binding protein by phage display. J Biol Chem 281, 1137\u20131144 (2006).","journal-title":"J Biol Chem"},{"key":"34238_CR43","doi-asserted-by":"crossref","unstructured":"Wu, A. L., Coulter, S., Liddle, C. & Wong, A. FGF19 regulates cell proliferation, glucose and bile acid metabolism via FGFR4-dependent and independent pathways. 6, 1\u201311 (2011).","DOI":"10.1371\/journal.pone.0017868"},{"key":"34238_CR44","doi-asserted-by":"publisher","first-page":"986","DOI":"10.1101\/gad.1773909","volume":"23","author":"J Miao","year":"2009","unstructured":"Miao, J. et al. Bile acid signaling pathways increase stability of Small Heterodimer Partner (SHP) by inhibiting ubiquitin-proteasomal degradation. Genes Dev 23, 986\u2013996 (2009).","journal-title":"Genes Dev"},{"key":"34238_CR45","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1007\/s11010-014-2044-0","volume":"393","author":"X Lin","year":"2014","unstructured":"Lin, X. et al. FGF21 inhibits apolipoprotein(a) expression in HepG2 cells via the FGFR1-ERK1\/2-Elk-1 pathway. Mol Cell Biochem 393, 33\u201342 (2014).","journal-title":"Mol Cell Biochem"},{"key":"34238_CR46","doi-asserted-by":"publisher","first-page":"2050","DOI":"10.1210\/me.2010-0142","volume":"24","author":"K Fon Tacer","year":"2010","unstructured":"Fon Tacer, K. et al. Research resource: Comprehensive expression atlas of the fibroblast growth factor system in adult mouse. Mol Endocrinol 24, 2050\u20132064 (2010).","journal-title":"Mol Endocrinol"},{"key":"34238_CR47","doi-asserted-by":"publisher","first-page":"26687","DOI":"10.1074\/jbc.M704165200","volume":"282","author":"H Kurosu","year":"2007","unstructured":"Kurosu, H. et al. Tissue-specific expression of betaKlotho and fibroblast growth factor (FGF) receptor isoforms determines metabolic activity of FGF19 and FGF21. J Biol Chem 282, 26687\u201326695 (2007).","journal-title":"J Biol Chem"},{"key":"34238_CR48","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1038\/nrd.2015.9","volume":"15","author":"C Degirolamo","year":"2016","unstructured":"Degirolamo, C., Sabb\u00e0, C. & Moschetta, A. Therapeutic potential of the endocrine fibroblast growth factors FGF19, FGF21 and FGF23. Nat Rev Drug Discov 15, 51\u201369 (2016).","journal-title":"Nat Rev Drug Discov"},{"key":"34238_CR49","doi-asserted-by":"publisher","first-page":"1621","DOI":"10.1126\/science.1198363","volume":"331","author":"S Kir","year":"2011","unstructured":"Kir, S. et al. FGF19 as a postprandial, insulin-independent activator of hepatic protein and glycogen synthesis. Science (New York, NY) 331, 1621\u20131624 (2011).","journal-title":"Science (New York, NY)"},{"key":"34238_CR50","doi-asserted-by":"publisher","first-page":"4931","DOI":"10.1210\/en.2009-0532","volume":"150","author":"MK Badman","year":"2009","unstructured":"Badman, M. K., Koester, A., Flier, J. S., Kharitonenkov, A. & Maratos-Flier, E. Fibroblast growth factor 21-deficient mice demonstrate impaired adaptation to ketosis. Endocrinology 150, 4931\u20134940 (2009).","journal-title":"Endocrinology"},{"key":"34238_CR51","doi-asserted-by":"publisher","first-page":"2781","DOI":"10.2337\/db10-0193","volume":"59","author":"FM Fisher","year":"2010","unstructured":"Fisher, F. M. et al. Obesity is a fibroblast growth factor 21 (FGF21)-resistant state. Diabetes 59, 2781\u20132789 (2010).","journal-title":"Diabetes"},{"key":"34238_CR52","doi-asserted-by":"publisher","first-page":"250","DOI":"10.2337\/db08-0392","volume":"58","author":"J Xu","year":"2009","unstructured":"Xu, J. et al. Fibroblast growth factor 21 reverses hepatic steatosis, increases energy expenditure, and improves insulin sensitivity in diet-induced obese mice. Diabetes 58, 250\u2013259 (2009).","journal-title":"Diabetes"},{"key":"34238_CR53","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1016\/j.cmet.2013.04.005","volume":"17","author":"Z Lin","year":"2013","unstructured":"Lin, Z. et al. Adiponectin Mediates the Metabolic Effects of FGF21 on Glucose Homeostasis and Insulin Sensitivity in Mice. Cell Metab 17, 779\u2013789 (2013).","journal-title":"Cell Metab"},{"issue":"11","key":"34238_CR54","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1016\/j.tem.2015.09.007","volume":"26","author":"Alexei Kharitonenkov","year":"2015","unstructured":"Kharitonenkov, A. & Dimarchi, R. FGF21 Revolutions: Recent Advances Illuminating FGF21 Biology and MedicinalProperties. Trends Endocrinol Metab 1\u201310, https:\/\/doi.org\/10.1016\/j.tem.2015.09.007 (2015).","journal-title":"Trends in Endocrinology & Metabolism"},{"key":"34238_CR55","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.it.2014.12.008","volume":"36","author":"J Mauer","year":"2015","unstructured":"Mauer, J., Denson, J. L. & Br\u00fcning, J. C. Versatile functions for IL-6 in metabolism and cancer. Trends Immunol 36, 92\u2013101 (2015).","journal-title":"Trends Immunol"},{"key":"34238_CR56","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1038\/nm0102-75","volume":"8","author":"V Wallenius","year":"2002","unstructured":"Wallenius, V. et al. Interleukin-6-deficient mice develop mature-onset obesity. Nat Med 8, 75\u201379 (2002).","journal-title":"Nat Med"},{"key":"34238_CR57","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1016\/S0006-291X(02)00230-9","volume":"293","author":"K Wallenius","year":"2002","unstructured":"Wallenius, K., Wallenius, V., Sunter, D., Dickson, S. L. & Jansson, J.-O. Intracerebroventricular interleukin-6 treatment decreases body fat in rats. Biochem Biophys Res Commun 293, 560\u2013565 (2002).","journal-title":"Biochem Biophys Res Commun"},{"key":"34238_CR58","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1007\/s00125-009-1580-8","volume":"53","author":"M Sadagurski","year":"2010","unstructured":"Sadagurski, M. et al. Human IL6 enhances leptin action in mice. Diabetologia 53, 525\u2013535 (2010).","journal-title":"Diabetologia"},{"key":"34238_CR59","doi-asserted-by":"publisher","first-page":"1630","DOI":"10.2337\/db06-1733","volume":"56","author":"S Glund","year":"2007","unstructured":"Glund, S. et al. Interleukin-6 directly increases glucose metabolism in resting human skeletal muscle. Diabetes 56, 1630\u20131637 (2007).","journal-title":"Diabetes"},{"key":"34238_CR60","doi-asserted-by":"publisher","first-page":"1481","DOI":"10.1038\/nm.2513","volume":"17","author":"H Ellingsgaard","year":"2011","unstructured":"Ellingsgaard, H. et al. Interleukin-6 enhances insulin secretion by increasing glucagon-like peptide-1 secretion from L cells and alpha cells. Nat Med 17, 1481\u20131489 (2011).","journal-title":"Nat Med"},{"key":"34238_CR61","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1016\/j.bbadis.2015.01.017","volume":"1852","author":"Y Ma","year":"2015","unstructured":"Ma, Y., Gao, M., Sun, H. & Liu, D. Interleukin-6 gene transfer reverses body weight gain and fatty liver in obese mice. Biochim Biophys Acta 1852, 1001\u20131011 (2015).","journal-title":"Biochim Biophys Acta"},{"key":"34238_CR62","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/j.bbi.2009.09.002","volume":"24","author":"J Hidalgo","year":"2010","unstructured":"Hidalgo, J. et al. Transgenic mice with astrocyte-targeted production of interleukin-6 are resistant to high-fat diet-induced increases in body weight and body fat. Brain Behav. Immun. 24, 119\u2013126 (2010).","journal-title":"Brain Behav. Immun."},{"key":"34238_CR63","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1016\/j.cmet.2010.06.011","volume":"12","author":"FT Wunderlich","year":"2010","unstructured":"Wunderlich, F. T. et al. Interleukin-6 signaling in liver-parenchymal cells suppresses hepatic inflammation and improves systemic insulin action. Cell Metab 12, 237\u2013249 (2010).","journal-title":"Cell Metab"},{"key":"34238_CR64","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1016\/j.cmet.2013.08.014","volume":"18","author":"ML Reitman","year":"2013","unstructured":"Reitman, M. L. FGF21 mimetic shows therapeutic promise. Cell Metab 18, 307\u2013309 (2013).","journal-title":"Cell Metab"},{"key":"34238_CR65","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1016\/S0002-9440(10)61177-7","volume":"160","author":"K Nicholes","year":"2002","unstructured":"Nicholes, K. et al. A mouse model of hepatocellular carcinoma: ectopic expression of fibroblast growth factor 19 in skeletal muscle of transgenic mice. Am J Pathol 160, 2295\u20132307 (2002).","journal-title":"Am J Pathol"},{"key":"34238_CR66","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.1172\/JCI23606","volume":"115","author":"A Kharitonenkov","year":"2005","unstructured":"Kharitonenkov, A. et al. FGF-21 as a novel metabolic regulator. J Clin Invest 115, 1627\u20131635 (2005).","journal-title":"J Clin Invest"},{"key":"34238_CR67","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1038\/nature13540","volume":"513","author":"JM Suh","year":"2014","unstructured":"Suh, J. M. et al. Endocrinization of FGF1 produces a neomorphic and potent insulin sensitizer. Nature 513, 436\u2013439 (2014).","journal-title":"Nature"},{"key":"34238_CR68","doi-asserted-by":"publisher","first-page":"3296","DOI":"10.1038\/onc.2009.184","volume":"28","author":"DC Stylianou","year":"2009","unstructured":"Stylianou, D. C. et al. Effect of single-chain antibody targeting of the ligand-binding domain in the anaplastic lymphoma kinase receptor. Oncogene 28, 3296\u20133306 (2009).","journal-title":"Oncogene"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-34238-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-34238-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-34238-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,21]],"date-time":"2022-12-21T06:07:09Z","timestamp":1671602829000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-34238-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10,29]]},"references-count":68,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2018,12]]}},"alternative-id":["34238"],"URL":"https:\/\/doi.org\/10.1038\/s41598-018-34238-5","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,10,29]]},"assertion":[{"value":"27 February 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 October 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 October 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A.W. declares competing interests since he is named as inventor on a Georgetown University patent related to treatments for lowering glucose levels using FGFBP3, described in this manuscript. All other authors have declared that no conflict of interest exists.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"15973"}}